Intravenous and Inhaled Antimicrobials at Home in Cystic Fibrosis Patients

被引:1
|
作者
Thigpen, Jim [1 ]
Odle, Brian [1 ]
机构
[1] East Tennessee State Univ, Johnson City, TN USA
关键词
cystic fibrosis; antimicrobial therapy; intravenous antibiotics; aerosolized antibiotics; home health; Pseudomonas aeruginosa; Staphylococcus aureus;
D O I
10.1177/1084822313501322
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
The primary clinical characteristics of cystic fibrosis (CF) are malnutrition caused by malabsorption secondary to pancreatic insufficiency, chronic pulmonary infections, and male infertility. The major cause of morbidity and mortality are bronchiectasis and obstructive pulmonary disease. Lung disease in CF is manifested by this chronic lung disease progression, with intermittent episodes of acute worsening of symptoms called pulmonary exacerbations. Once the patient has stabilized, and if suitable care can be arranged, these interventions are often transitioned to the home. This review summarizes important points pertinent to the use of intravenous and inhaled antimicrobials that may be encountered by prescribers, nurses, technicians, and case managers in the home health setting. Appropriate dosing, indications, adverse drug reactions, monitoring parameters, and practicality of both intravenous and inhaled antimicrobials are discussed.
引用
收藏
页码:101 / 109
页数:9
相关论文
共 50 条
  • [1] The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis
    VanDevanter, Eden J.
    Heltshe, Sonya L.
    Skalland, Michelle
    Lechtzin, Noah
    Nichols, Dave
    Goss, Christopher H.
    JOURNAL OF CYSTIC FIBROSIS, 2021, 20 (06) : 932 - 936
  • [2] Off-label use of intravenous antimicrobials for inhalation in patients with cystic fibrosis
    McKinzie, Cameron J.
    Chen, Lori
    Ehlert, Kim
    Grisso, Alison G.
    Linafelter, Alaina
    Lubsch, Lisa
    O'Brien, Catherine E.
    Pan, Alice C.
    Wright, Brittany A.
    Elson, E. Claire
    PEDIATRIC PULMONOLOGY, 2019, 54 : S27 - S45
  • [3] USE OF INHALED TOBRAMYCIN IN PATIENTS WITH CYSTIC FIBROSIS
    Chermensky, A. G.
    Gembitskaya, M. E.
    TERAPEVTICHESKII ARKHIV, 2010, 82 (08) : 76 - 78
  • [4] HOME INTRAVENOUS ANTIBIOTIC-TREATMENT OF PATIENTS WITH CYSTIC-FIBROSIS
    STRANDVIK, B
    HJELTE, L
    MALMBORG, AS
    WIDEN, B
    ACTA PAEDIATRICA, 1992, 81 (04) : 340 - 344
  • [5] Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis
    Wagener, Jeffrey S.
    Rasouliyan, Lawrence
    VanDevanter, Donald R.
    Pasta, David J.
    Regelmann, Warren E.
    Morgan, Wayne J.
    Konstan, Michael W.
    PEDIATRIC PULMONOLOGY, 2013, 48 (07) : 666 - 673
  • [6] Home Intravenous Antibiotic Protocols for Acute Pulmonary Exacerbations in Patients With Cystic Fibrosis: A Scoping Review
    Odendaal, Michelle
    Tilbury, Zak
    Conway, Aaron
    HOME HEALTH CARE MANAGEMENT AND PRACTICE, 2025,
  • [7] Pharmacokinetics of inhaled colistin in patients with cystic fibrosis
    Ratjen, F
    Rietschel, E
    Kasel, D
    Schwiertz, R
    Starke, K
    Beier, H
    van Koningsbruggen, S
    Grasemann, H
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (02) : 306 - 311
  • [8] Efficiency of the home intravenous antibiotics treatment in cystic fibrosis
    Giron, Rosa Maria
    Cisneros, Carolina
    Al Nakeeb, Zaid
    Hoyos, Nieves
    Martinez, Concha
    Ancochea, Julio
    MEDICINA CLINICA, 2006, 127 (15): : 567 - 571
  • [9] Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis
    Hennig, Stefanie
    McKay, Karen
    Vidmar, Suzanna
    O'Brien, Katie
    Stacey, Sonya
    Cheney, Joyce
    Wainwright, Claire E.
    JOURNAL OF CYSTIC FIBROSIS, 2014, 13 (04) : 428 - 434
  • [10] Use of Inhaled Tobramycin in Cystic Fibrosis
    Shteinberg, Michal
    Elborn, J. Stuart
    ADVANCES IN THERAPY, 2015, 32 (01) : 1 - 9